Investments from Pharmaceutical Entities in R&D Endeavors
Increasing to Enhance Uveitis Treatment Efficacy and Patient
Outcomes
ROCKVILLE, Md., July 16,
2024 /PRNewswire/ -- According to a recently
released industry report by Fact.MR, the global Uveitis
Treatment Market is poised to be valued at US$ 791 million in 2024 and further expand at
5.8% CAGR from 2024 to 2034. Technological advancements in
therapy approaches, particularly in the creation of
sustained-release drug delivery devices, are key factors driving
uveitis treatment market growth.
Advanced treatment methods, which include biodegradable
microspheres and intravitreal implants, provide significant
advantages since they directly administer prolonged pharmaceutical
exposure to the affected eye tissues. Reducing the need for
repeated injections or systemic medications lowers the risk of
undesirable systemic effects while increasing patient compliance
and convenience.
The rising incidence of uveitis in some countries due to the
increasing aging population, a rise in the prevalence of autoimmune
disorders, and a focus on improving diagnostic capabilities are
major aspects driving the growth of the market for uveitis
treatment. Increased funding from pharmaceutical companies and
organizations for research and development initiatives aimed at
uveitis treatment is driving the exploration of new medicinal
agents and treatment strategies.
For More Insights into the Market, Request a Sample of this
Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10187
Key Takeaways from the Market Study
- The global market for uveitis treatment is projected to reach
US$ 1.4 billion by
2034-end.
- North America is estimated to
hold 36.8% of the global market share in 2024.
- Demand for uveitis treatment in East
Asia is estimated at a market value of US$ 117 million in 2024.
- The Canada market is evaluated
to generate revenue of US$ 90 million
by 2034-end.
- The market in South Korea is
forecasted to expand at a CAGR of 9.4% from 2024 to 2034.
- Based on disease, the anterior uveitis segment is forecasted to
hold 59.5% of the global market share by 2034.
- In the North American region, the
United States is expected to lead the market with a 73.4%
revenue share in 2024.
"Revenue from uveitis treatment is growing at a steady
pace as a result of ongoing advancements such as sustained-release
medication delivery techniques that improve patient convenience and
therapeutic efficacy," says a Fact.MR analyst.
Leading Players Driving Innovation in the Uveitis Treatment
Market
Key players in the uveitis treatment industry are Sun
Pharmaceutical Industries Ltd., EyePoint Pharmaceuticals, Inc.,
Ophthotech Corporation, Regeneron Pharmaceuticals, Inc., Takeda
Pharmaceutical Company Limited, Inflammasome Therapeutics Inc.,
Graybug Vision, Inc., TopiVert Pharma Ltd., Pfizer Inc., Bausch
Health Companies Inc.
Hospital Pharmacies Account for Substantial Market
Share
Hospital pharmacies are generating substantial revenue compared
to other distribution channels such as retail pharmacies, online
pharmacies, and drug stores. Hospital pharmacies face a constant
need for uveitis medications since uveitis is a fairly common
condition that requires ongoing care and because hospitals often
have a big patient base.
Hospitals benefit financially from treating an increasing number
of uveitis patients who require continuous access to the prescribed
medications. Hospital pharmacies benefit from discounted rates on
these medications due to contracts with specific suppliers of
uveitis medications.
Uveitis Treatment Industry News:
- Targeting non-infectious uveitis, including uveitic glaucoma,
Tarsier Pharma received FDA permission in January 2024 for the Tarsier-04 Phase 3 trial of
the TRS01 ocular solution under the Special Protocol Assessment
(SPA).
- The FDA approved triamcinolone acetonide injectable suspension,
or XIPER, in October 2021 for use as
a suprachoroidal medication to treat retinal edema associated with
uveitis.
- Targeting non-infectious posterior segment uveitis (NIPU) and
diabetic macular edema (DME), Alimera Sciences Europe Ltd. launched
ILUVIEN in the Netherlands in
December 2020 to expand
geographically to reach more doctors and patients.
Get Customization on this Report for Specific Research
Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10187
Global Market Analysis 2019 to 2023 and Forecast 2024 to
2034, by Treatment:
- Corticosteroids
- Immunosuppressants
- Monoclonal Antibodies
- Cycloplegic Agents
- Antibiotics
- Antivirals
- Antifungals
- Analgesics
Global Market Analysis 2019 to 2023 and Forecast 2024 to
2034, by Disease:
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
Global Market Analysis 2019 to 2023 and Forecast 2024 to
2034, by Cause:
- Infectious Uveitis
- Non-infectious Uveitis
Global Market Analysis 2019 to 2023 and Forecast 2024 to
2034, by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
More Valuable Insights:
Fact.MR, in its new offering, presents an unbiased analysis of
the uveitis treatment market, presenting historical demand data
(2019 to 2023) and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on
treatment (corticosteroids, immunosuppressants, monoclonal
antibodies, cycloplegic agents, antibiotics, antivirals,
antifungals, analgesics), disease (anterior uveitis, posterior
uveitis, intermediate uveitis, panuveitis), cause (infectious
uveitis, non-infectious uveitis), and distribution channel
(hospital pharmacies, retail pharmacies, online pharmacies, drug
stores), across seven major regions of the world (North America, Western Europe, Eastern Europe, East
Asia, Latin America,
South Asia & Pacific, and
MEA).
Check out More Related Studies Published by Fact.MR:
Eye Health Supplements Market stands at US$ 1.9 billion in 2023 and is forecasted to
reach US$ 3.5 billion by the end of
2033, increasing at a CAGR of 6.2%.
Dry Eye Syndrome Treatment Market is anticipated to be
worth US$ 4,027.2 million in 2024 and
is expected to expand to an astounding size of US$ 10,961.2 million by 2034.
Rare Neurological Disease Treatment Market is
projected to expand at a stellar CAGR of over 8.5% and is
anticipated to grow 2.3x between 2018 and 2028.
Ophthalmic Drugs Market is valued at US$ 38 billion in 2023 and is thus anticipated to
reach US$ 72 billion by 2033.
Ocular Drug Delivery Technology Market is poised to
flourish at a CAGR of 8.2% to reach a value of US$ 39 Billion by 2032.
Refsum Disease Treatment Market is predicted to
accelerate at a CAGR of 5.6% and reach a market valuation of
US$ 2.56 billion by the end of
2033.
About Us:
Fact.MR is a distinguished market research company
renowned for its comprehensive market reports and invaluable
business insights. As a prominent player in business intelligence,
we deliver deep analysis, uncovering market trends, growth paths,
and competitive landscapes. Renowned for its commitment to accuracy
and reliability, we empower businesses with crucial data and
strategic recommendations, facilitating informed decision-making
and enhancing market positioning.
With its unwavering dedication to providing reliable market
intelligence, FACT.MR continues to assist companies in navigating
dynamic market challenges with confidence and achieving long-term
success. With a global presence and a team of experienced analysts,
FACT.MR ensures its clients receive actionable insights to
capitalize on emerging opportunities and stay
competitive.
Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow
Us: LinkedIn | Twitter | Blog
View original
content:https://www.prnewswire.com/news-releases/uveitis-treatment-market-size-is-estimated-at-1-4-billion-by-2034--growing-at-a-7-cagr-says-factmr-302194720.html
SOURCE Fact.MR